Although the sFlt-1/PlGF ratio offers higher sensitivity (AUC = 0.83, 95% CI: 0.77–0.88) (7), our model presents a cost-effective alternative for initial PE risk stratification in CH patients. This evidence concerns the gene PGF and cyclic hematopoiesis.